TLL-018 in Patients With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to csDMARDs

NCT07748728 · clinicaltrials.gov ↗

PHASE2

Phase

ENROLLING_BY_INVITATION

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis (RA)

Interventions

DRUG: TLL-018
DRUG: Placebo

Sponsor

Hangzhou Highlightll Pharmaceutical Co., Ltd